1. C01 Glutamine codon usage and somatic mosaicism of the HTT cag repeat are modifiers of huntington disease severity. (September 2018) Authors: Ciosi, Marc; Maxwell, Alastair; Cumming, Sarah; Moss, Davina J Hensman; Alshammari, Asma Mubarak; Flower, Michael D; Durr, Alexandra; Leavitt, Blair R; Roos, Raymund A; Holmans, Peter; Jones, Lesley; Langbehn, Douglas R; Kwak, Seung; Tabrizi, Sarah J; Monckton, Darren G Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 89(2018)Supplement 1 Page Start: A26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities. Issue 7 (July 2022) Authors: Tabrizi, Sarah J; Estevez-Fraga, Carlos; van Roon-Mom, Willeke M C; Flower, Michael D; Scahill, Rachael I; Wild, Edward J; Muñoz-Sanjuan, Ignacio; Sampaio, Cristina; Rosser, Anne E; Leavitt, Blair R Journal: Lancet neurology Issue: Volume 21:Issue 7(2022) Page Start: 645 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗